Up to One in Three Adults Over 75 Harbour significant Alzheimer's pathology
without Showing Signs of Memory loss.
Amyloid and tau biomarkers reveal pathology. They do not reveal whether the memory network is still functioning.
Amyloid/tau plaques: Alzheimer’s pathology. Canopy: functional memory-network integrity. Significant pathology and preserved cognitive function can coexist.
MindScreener
Toward point-of-care dementia screening
using non-invasive, functional EEG
THE VISION
A more accessible route to biomarker assessment.
MindScreener is leveraging Electroencephalogram(EEG) as ascalable first-stage signal for amyloid-status research, alongside Positron Emission Tomography(PET), Cerebrospinal Fluid(CSF) or appropriately validated blood biomarkers. Its current platform is for Research Use Only and is not a validated diagnostic device
Non-invasive EEG measurement
Standardised research workflow
Independent validation programme
THE FUTURE OF EARLY DIAGNOSIS
“The future of early diagnosis of Alzheimer’s disease and other neurodegenerative disorders islikely to rely on a combination of molecular biomarkers and functional readouts.”
Prof. Bart De Strooper, MD, PhD, CBE
This statement reflects a general scientific perspective on the field. It does not constitute an assessment or endorsement of MindScreener, its technology, products, or scientific claims.
Bring functional brain assessment closer to the point of care.
MindScreener is developing a reproducible, scalable EEG pathway to help identify who should be prioritised for confirmatory biomarker testing. Building on encouraging research findings, we are advancing independent clinical validation and the regulatory programme for a medical device designed to complement blood biomarkers with a functional readout of memory-network integrity.
A controlled, patent-pending EEG workflow.
Standardised acquisition, signal-quality assessment, spectral feature extraction and machine-learning analysis in one traceable research process.
01
Record EEG
Resting and stimulation
protocols with recording
metadata.
02
Verify quality
Electrode, channel, artefact
and environmental checks.
03
Extract features
Periodic power, aperiodic
exponent and stimulation-
response measures.
04
Classify pattern
Reference-cohort output with
Quality Control context or
result withholding.
Illustrative RUO research interface. Client-facing UI subject to
clinical and regulatory validation.
EVIDENCE
Clear about what is known and what is underway.
PUBLISHED ASSOCIATION STUDY
EEG and tau-PET findings
A 64-participant high-density EEG study reported region-specific aperiodic differences and associations with tau burden. Our model achieved ROC-AUC of 82% in distinguishing between Alzheimer’s Disease and Cognitively Unimpaired individuals.
INTERNAL EXPLORATORY ANALYSIS
Retrospective classifier research
A separate 48-participant, two-centre analysis produced exploratory estimates. MindScreener validates analysis and classifier performance through independent clinical trials.
ONGOING VALIDATION
Evidence still required
Repeatability, hardware bridging, multi-site reproducibility, prospective performance and clinical utility data underway.
Overall, this study suggests that EEG, and especially aperiodic activity, could become a useful noninvasive tool for detecting early functional changes in Alzheimer’s disease.
Overall, this study suggests that EEG, and especially aperiodic activity, could become a useful noninvasive tool for detecting early functional changes in Alzheimer’s disease.
Our model achieved ROC-AUC of 82% in distinguishing between Alzheimer’s Disease and
Cognitively Unimpaired individuals.
A staged path from research proof to clinical evidence
COMPLETE / ONGOING
Scientific discovery
Identify candidate EEG features
associated with pathology.
CURRENT
Research Use Only validation
Evaluate independent cohorts,
sites, hardware and protocols.
UNDER VALIDATION
Prospective clinical validation
Establish analytical performance,
clinical performance and utility.
FUTURE INTENDED USE
Regulated clinical product
Launch only after validation and
regulatory clearance.
Research & Intellectual Property behind the programme
Published findings, internal exploratory results and future validation are presented as distinct evidence categories.
Published research 2026
Author: Tjasa Mlinaric et al
Role: MindScreener SAB
Early aperiodic EEG changes in preclinical and prodromal Alzheimer’s disease
Resting and visual-stimulation EEG were collected alongside dynamic tau PET. The study reported region-specific aperiodic differences and associations with tau burden. It did not validate the MindScreener classifier.
Published research 2014
Author: Dugger BN et al
Role: Not related to company
Clinicopathological Outcomes of Prospectively Followed Normal Elderly Brain Bank Volunteers
Autopsy studies indicate that roughly one-third of cognitively unimpaired older adults may
nevertheless harbour substantial Alzheimer-type neuropathology.
Published research 2006
Author: Bennet et al
Role: Not related to company
Neuropathology of older persons without cognitive impairment from two community-based studies
Read more evidence
Published research 2015
Author: Jansen et al
Role: Not releated to company
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia
Combines 55 studies and included 2,914 cognitively normal participants. Amyloid positivity increased from 10% at age 50 to 44% at age 90; other syntheses place it around 20–30% at ages 70–80. This establishes that substantial amyloid can exist for years without dementia.
Published research 2024
Author: O’Neill et al
Role: Not releated to company
Cognitive Resilience to Alzheimer’s Disease Characterized by Cell-Type Abundance
This recent paper summarizes the field estimate directly: approximately 25% of cognitively normal people aged 75 or older show Alzheimer-like amyloid, tau and neuronal pathology at autopsy. Its primary analysis also identifies cellular and genetic correlates of resilience.
Published research 2019
Author: Bowles et al
Role: Not releated to company
Cognitive Resilience to Alzheimer’s Disease Pathology in the Human Brain
Among 276 people with intermediate/high Alzheimer pathology, 68—25% of this pathology-positive group—remained dementia-free with high cognition close to death. College education was associated with twice the odds of resilience, while microinfarcts and hippocampal sclerosis markedly reduced it.
Published research 2013
Author: Wilson et al
Role: Not releated to company
Life-Span Cognitive Activity, Neuropathologic Burden, and Cognitive Aging
In 294 people followed cognitively and then autopsied, greater early- and late-life cognitive activity predicted slower cognitive decline after controlling for amyloid, tau tangles, infarcts and Lewy bodies. Cognitive activity explained 14% of the remaining variation in decline.
Published research 2023
Author: Paolillo et al
Role: Not releated to company
Multimodal Lifestyle Engagement Patterns Support Cognitive Stability Beyond Neuropathological Burden
This study followed 2,059 older adults; 791 subsequently had autopsies. Balanced physical, cognitive and social engagement was associated with slower cognitive decline even after adjustment for Alzheimer, vascular, Lewy-body and TDP-43 pathology. Because it is observational, it supports an association rather than proving causation.
Published research 2023
Author: Wagner et al
Role: Not releated to company
The Association of MIND Diet With Cognitive Resilience to Neuropathologies
In 578 deceased older adults with longitudinal cognitive testing and postmortem neuropathology, high adherence to the MIND diet was associated with better cognition and slower decline than expected from the pathology burden.
Published research 2024
Author: Boyle et al
Role: Not releated to company
Left Frontoparietal Control Network Connectivity Moderates the Effect of Amyloid on Cognitive Decline
In 1,021 cognitively unimpaired older adults followed for an average of 5.4 years, stronger left frontoparietal-control-network connectivity was associated with less amyloid-related cognitive decline. This is probably the strongest direct support for your “unique brain wiring” idea, although “functional network organization” is the scientific term.
INTELLECTUAL PROPERTY
Patent published: 12 February 2026
Owner: Mindspeller BCI BV
Publication No: WO2026032524A1
Method and system for activating and analyzing the default mode network of a subject for neurophysiological data analysis, pattern identification and characterization (MindScreener)
Status: Published
Patent published: 15 January 2026
Owner: Mindspeller BCI BV
Publication No: WO2026013188A1
Method for imagined speech fragment identification and semantic reconstruction.
Status: Published
Patent Granted 7 February 2024
Owner: Mindspeller BCI BV
US patent: US12260850B2
Dutch patent: NL2024573B1
Brain computer interface running a trained associative model applying multiway regression to simulate electrocorticography signal features from sensed EEG signals, and corresponding method.
Status: Published
Published Research
Peer-reviewed findings describing relationships between EEG measures and biomarker burden.
Internal exploratory analysis
Proprietary classifier research that remains subject to independent validation.
Longitudinal functional-
resilience monitoring.
MindSscreener studies will examine whether EEG-derived features change across repeated visits, disease progression or therapeutic programmes. The concept is not a current product output or validated clinical score but a product concept under development.
Icon key — Brain colour: amyloid/tau burden (green lower; grey higher; mixed intermediate) · Tree canopy: resilience (full = preserved; sparse = reduced). High pathology may coexist with preserved function.
Built for independent evaluation.
For academic research teams
Validate EEG-derived features in independent
cohorts and contribute to multi-site reproducibility evidence.
For sponsors and CROs
Evaluate EEG-supported enrichment research alongside confirmatory biomarker testing.
Illustrative scenario only — not demonstrated savings. All assumptions require sponsor-specific validation.
Building the functional layer of
dementia assessment.
MindScreener is a dedicated medical-device venture within the Mindspeller
NeuroTech group. We combine EEG and brain-computer-interface science,
machine learning, product engineering and regulatory expertise to advance an
investigational platform towards clinical validation and certification.
SCIENTIFIC ADVISORY BOARD
What makes MindScreener different
Non-invasive measurement
EEG records brain activity without radioactive tracers or lumbar puncture.
Automated biomarker extraction
Software converts raw neural activity into reproducible spectral features.
Active and resting protocols
The research programme examines spontaneous activity and controlled stimulation responses.
Transparent classification
Reference-pattern output is accompanied by Quality Control, model and recording metadata.
Scalable architecture
The longer-term objective is deployment across research centres, trial sites and clinical pathways after validation.
Evidence-led development
Published findings, preliminary classifier results and future intended use are presented separately.
Independent expertise for responsible development.
The advisory board brings clinical, neurological, psychiatric and digital-health perspectives to MindScreener’s research and development programme.
Clinical & scientific advisors
Prof. Marc Van Hulle, PhD
Co-founder and Chief Scientific Officer. Head of the Computational Neuroscience and BCI Laboratory at KU Leuven.
Holly Posner, MD, MS
Physician-scientist and senior clinical R&D leader across neurology and Alzheimer programmes.
Ludovic Ampe
Head of Neurology at Cascador Health; neurotechnology and digital- health operator.
Gill Livingston, MD, PhD
Professor in Psychiatry of Older People, UCL; honorary consultant psychiatrist.
Stephan Claes, PhD
Full Professor and Head of Psychiatry Research at KU Leuven; member of the Leuven Brain Institute.
A multidisciplinary product-development team.
MindScreener brings together company strategy, EEG and machine-learning science, product development and regulatory
expertise.
Prof. Marc Van Hulle, PhD
Co-Founder and Chief Scientific Officer — EEG biomarkers, neural-signal analysis and machine learning.
NN
candidate identified, interviews ongoing
CEO — Senior life-sciences and medtech leader, experienced in regulated diagnostics, product development and multidisciplinary team leadership.
NN
candidate identified, interviews ongoing
CTO — Biomedical engineer and PhD-trained AI researcher with experience in biomedical signals, imaging and clinical collaboration.
Hannes De Wachter, MSc
Co-Founder & Chief Corporate Development Officer
ATTP-registered technology-transfer professional leading people and organisation, corporate communications, technology licensing, strategic partnerships and investor relations.
Caydie Van Brabant, MSc
Business Developer: biomedical engineer and healthtech founder with experience in US market expansion, commercial partnerships and scaling digital-health solutions.
Bob Van Dyck, PhD
Product Developer translating EEG methods and experimental workflows into scalable neurotechnology products.
Tianyu Ma, PhD candidat
Research Scientist, EEG & Machine Learning: PhD researcher developing EEG biomarkers, neural-signal analysis and machine-learning methods for functional cognitive assessment.
Dries Weytjens, MSc
Product Developer: bioscience engineer with postgraduate training in innovation and entrepreneurship, translating biomedical innovation into practical, scalable neurotechnology products.
Beatrice Marconi, MSc
Biomedical Engineer, R&D & Quality: combining hands-on physiological-signal processing and medtech development with growing responsibility for MindScreener design controls and quality assurance.
Interested in an independent validation or research
partnership?
Tell us about your cohort, reference-biomarker pathway, EEG setup and research objective.
RESEARCH QUALIFICATION
Discuss an RUO validation or research partnership
This form is for academic researchers, clinical research centres, pharma sponsors, CROs and
diagnostic-development partners. Do not submit patient health data.
Before you begin
✓ Research teams and professional partners only
✓ No patient screening or clinical intake
✓ No patient-identifiable health data
✓ Response target: within 2 business days
Why we ask technical questions
Cohort, reference biomarker and EEG details help us assess feasibility and route the inquiry to the appropriate scientific or partnership team.
Research qualification form
Fields are grouped to make the inquiry easier to complete.
